People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.
Patients with localized muscle-invasive bladder cancer who received radiation plus the immune checkpoint inhibitors durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical study published in Clinical Cancer Research, a journal of the AACR.
